Cytomegalovirus in hematopoietic stem cell transplant recipients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

172 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.Viruses · 2024
   Pooled it
2. A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients.Clinical pharmacokinetics · 2021
   Pooled it
3. Infectious Complications in Paediatric Haematopoetic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status.Frontiers in pediatrics · 2021
   Pooled it
4. Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study.Antimicrobial agents and chemotherapy · 2025
   Trial
5. Mathematical Modeling of Within-Host, Untreated, Cytomegalovirus Infection Dynamics after Allogeneic Transplantation.Viruses · 2021
   Trial
6. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.Blood advances · 2021
   Trial
7. CMV viral load kinetics as surrogate endpoints after allogeneic transplantation.The Journal of clinical investigation · 2021
   Trial
8. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
   Trial
9. Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.Antimicrobial agents and chemotherapy · 2020
   Trial
10. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial.Annals of internal medicine · 2020
    Trial
11. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.Leukemia · 2020
    Trial
12. Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study.Bone marrow transplantation · 2018
    Trial
13. Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial.International journal of hematology · 2017
    Trial
14. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.The Lancet. Haematology · 2016
    Trial
15. Is CMV PCR Monitoring Necessary in Patients with Hematological Malignancy Receiving Chemotherapy? A Prospective Single-Center StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Article
16. Bidirectional Temporal Association Between Cytomegalovirus Reactivation and Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Real-World Cohort Study.Viruses · 2026
    Article
17. A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
18. Human Cytomegalovirus UL4 is Required for Viral Reactivation via Cellular Reprogramming in Latently Infected CD34+ Progenitor Cells and Humanized Mice.bioRxiv : the preprint server for biology · 2026
    Article
19. Ultra-widefield retinal imaging for early detection of asymptomatic cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation: a prospective pilot feasibility study.Journal of ophthalmic inflammation and infection · 2026
    Article
20. The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis.Open forum infectious diseases · 2026
    Article

112 more citing papers are in PubMed but not listed here.

Corrections and comments

• Reprint of
  Cytomegalovirus in hematopoietic stem cell transplant recipients.2010

Authors and funding

3 authors.

Funding

Abstract